目的 探討心可舒丸聯(lián)合貝尼地平治療變異型心絞痛的臨床療效。方法 選擇2020年11月—2023年11月青島市第八人民醫(yī)院收治的80例變異型心絞痛患者為研究對象，抽簽法隨機分為對照組（40例）和治療組（40例）。對照組口服鹽酸貝尼地平片，1次/d。在對照組的基礎(chǔ)上，治療組口服心可舒丸，4粒/次，3次/d。兩組患者連續(xù)治療6周。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀評分，心絞痛發(fā)作持續(xù)時間和發(fā)作次數(shù)，血清C反應(yīng)蛋白（CRP）、白細胞介素-6（IL-6）、可溶性細胞間黏附分子-1（sICAM-1）、內(nèi)皮素-1（ET-1）、一氧化氮（NO）、心肌肌鈣蛋白Ⅰ（cTnI）水平。結(jié)果 與對照組相比，治療組總有效率明顯升高（95.00% vs 80.00%，P＜0.05）。治療后，兩組患者胸悶、胸痛及心悸評分明顯降低（P＜0.05），且治療組評分明顯低于對照組（P＜0.05）。治療后，兩組患者心絞痛發(fā)作持續(xù)時間和發(fā)作次數(shù)均明顯下降（P＜0.05），且與對照組相比，治療組降低更明顯（P＜0.05）。治療后，兩組患者血清CRP、IL-6、sICAM-1、ET-1和cTnI水平明顯降低，而NO水平明顯升高（P＜0.05），且與對照組相比，治療組血清學水平改善更明顯（P＜0.05）。結(jié)論 心可舒丸聯(lián)合貝尼地平治療變異型心絞痛的臨床療效較好，有助于改善臨床癥狀，減輕心絞痛，改善血清炎性因子和ET-1、NO、cTnI水平，且具有較好的安全性。

Objective To investigate the clinical efficacy of Xinkeshu Pills combined with benidipine in treatment of variant angina pectoris. Methods Patients (80 cases) with variant angina pectoris in Qingdao Eighth People’s Hospital from November 2020 to November 2023 were divided into control (40 cases) and treatment (40 cases) group by drawing lots. Patients in the control group were po administered with Benidipine Hydrochloride Tablets, once dalily. Patients in the treatment group were po administered with Xinkeshu Pills on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical evaluations were evaluated, the clinical symptom scores, duration and f frequency of angina attacks, the levels of serum CRP, IL-6, sICAM-1, ET-1, NO and cTnI in two groups before and after treatment were compared. Results Compared with the control group, the total clinical effective rate of the treatment group was significantly increased (95.00% vs 80.00%, P < 0.05). After treatment, the scores of chest tightness, chest pain, and palpitations in two groups were significantly reduced (P < 0.05), and the scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the duration and frequency of angina attacks in two groups were significantly decreased (P < 0.05), and compared with the control group, the treatment group showed a more significant decrease (P < 0.05). After treatment, the levels of serum CRP, IL-6, sICAM-1, ET-1, and cTnI in two groups of patients were significantly reduced, while the level of NO was significantly increased (P < 0.05). Compared with the control group, the serum levels in the treatment group improved more significantly (P < 0.05). Conclusion The clinical efficacy of Xinkeshu Pills combined with benidipine in the treatment of variant angina pectoris is significant, which helps to improve clinical symptoms, alleviate angina pectoris, improve serum inflammatory factors and ET-1, NO, cTnI levels, and has good safety.

R972

山東省醫(yī)學會臨床科研資金-齊魯專項（YXH2021ZX02210）